First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy

IF 50 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Nature Medicine Pub Date : 2025-02-05 DOI:10.1038/s41591-024-03484-8
Genís Prat-Ortega, Scott Ensel, Serena Donadio, Luigi Borda, Amy Boos, Prakarsh Yadav, Nikhil Verma, Jonathan Ho, Erick Carranza, Sarah Frazier-Kim, Daryl P. Fields, Lee E. Fisher, Doug J. Weber, Jeffrey Balzer, Tina Duong, Steven D. Weinstein, Mikael J. L. Eliasson, Jacqueline Montes, Karen S. Chen, Paula R. Clemens, Peter Gerszten, George Z. Mentis, Elvira Pirondini, Robert M. Friedlander, Marco Capogrosso
{"title":"First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy","authors":"Genís Prat-Ortega, Scott Ensel, Serena Donadio, Luigi Borda, Amy Boos, Prakarsh Yadav, Nikhil Verma, Jonathan Ho, Erick Carranza, Sarah Frazier-Kim, Daryl P. Fields, Lee E. Fisher, Doug J. Weber, Jeffrey Balzer, Tina Duong, Steven D. Weinstein, Mikael J. L. Eliasson, Jacqueline Montes, Karen S. Chen, Paula R. Clemens, Peter Gerszten, George Z. Mentis, Elvira Pirondini, Robert M. Friedlander, Marco Capogrosso","doi":"10.1038/s41591-024-03484-8","DOIUrl":null,"url":null,"abstract":"Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease causing motoneuron dysfunction, muscle weakness, fatigue and early mortality. Three new therapies can slow disease progression, enabling people to survive albeit with lingering motor impairments. Indeed, weakness and fatigue are still among patients’ main concerns. Here we show that epidural spinal cord stimulation (SCS) improved motoneuron function, thereby increasing strength, endurance and gait quality, in three adults with type 3 SMA. Preclinical works demonstrated that SMA motoneurons show low firing rates because of a loss of excitatory input from primary sensory afferents. In the present study, we hypothesized that correcting this loss with electrical stimulation of the sensory afferents could improve motoneuron function. To test this hypothesis, we implanted three adults with SMA with epidural electrodes over the lumbosacral spinal cord, targeting sensory axons of the legs. We delivered SCS for 4 weeks, 2 h per day during motor tasks. Our intervention led to improvements in strength (up to +180%), gait quality (mean step length: +40%) and endurance (mean change in 6-minute walk test: +26 m), paralleled by increased motoneuron firing rates. These changes persisted even when SCS was turned OFF. Notably, no adverse events related to the stimulation were reported. ClinicalTrials.gov identifier: NCT05430113 . Improved muscle function, strength and fatigue measures were observed after electrical spinal cord stimulation in individuals with spinal muscular atrophy.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"31 4","pages":"1246-1256"},"PeriodicalIF":50.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41591-024-03484-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease causing motoneuron dysfunction, muscle weakness, fatigue and early mortality. Three new therapies can slow disease progression, enabling people to survive albeit with lingering motor impairments. Indeed, weakness and fatigue are still among patients’ main concerns. Here we show that epidural spinal cord stimulation (SCS) improved motoneuron function, thereby increasing strength, endurance and gait quality, in three adults with type 3 SMA. Preclinical works demonstrated that SMA motoneurons show low firing rates because of a loss of excitatory input from primary sensory afferents. In the present study, we hypothesized that correcting this loss with electrical stimulation of the sensory afferents could improve motoneuron function. To test this hypothesis, we implanted three adults with SMA with epidural electrodes over the lumbosacral spinal cord, targeting sensory axons of the legs. We delivered SCS for 4 weeks, 2 h per day during motor tasks. Our intervention led to improvements in strength (up to +180%), gait quality (mean step length: +40%) and endurance (mean change in 6-minute walk test: +26 m), paralleled by increased motoneuron firing rates. These changes persisted even when SCS was turned OFF. Notably, no adverse events related to the stimulation were reported. ClinicalTrials.gov identifier: NCT05430113 . Improved muscle function, strength and fatigue measures were observed after electrical spinal cord stimulation in individuals with spinal muscular atrophy.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脊髓硬膜外刺激对脊髓性肌萎缩症患者的首次人体研究
脊髓性肌萎缩症(SMA)是一种遗传性神经退行性疾病,可导致运动神经元功能障碍、肌肉无力、疲劳和早期死亡。三种新疗法可以减缓疾病的进展,使人们能够在运动障碍挥之不去的情况下生存下来。事实上,虚弱和疲劳仍然是患者的主要担忧。本研究表明,硬膜外脊髓刺激(SCS)改善了3例3型SMA成人的运动神经元功能,从而增加了力量、耐力和步态质量。临床前研究表明,由于初级感觉传入的兴奋性输入缺失,SMA运动神经元表现出低放电率。在本研究中,我们假设通过电刺激感觉传入来纠正这种损失可以改善运动神经元的功能。为了验证这一假设,我们在3名患有SMA的成年人腰骶脊髓上植入硬膜外电极,目标是腿部的感觉轴突。我们连续4周,每天2小时在运动任务期间提供SCS。我们的干预导致力量(高达+180%)、步态质量(平均步长:+40%)和耐力(6分钟步行测试的平均变化:+26米)的改善,并伴有运动神经元放电率的增加。即使关闭SCS,这些变化仍然存在。值得注意的是,没有报道与刺激相关的不良事件。ClinicalTrials.gov识别码:NCT05430113。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nature Medicine
Nature Medicine 医学-生化与分子生物学
CiteScore
100.90
自引率
0.70%
发文量
525
审稿时长
1 months
期刊介绍: Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
期刊最新文献
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Quality health information for all is a fundamental determinant of health. Hope for control of a centuries-old epidemic. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Hope, hard lessons and the path to better nutrition.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1